Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function

Ibrutinib Inhibits Platelet Integrin αIIbβ3Outside-In Signaling and Thrombus Stability But Not Adhesion to CollagenSignificance

(2015) Alexander P. Bye et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia

(2015) J. R. Brown et al.   BLOOD

Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions

(2014) M. Levade et al.   BLOOD

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

(2014) Eleonora Marostica et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

(2014) S Kamel et al.   LEUKEMIA

p21 Activated Kinase Signaling Coordinates Glycoprotein Receptor VI–Mediated Platelet Aggregation, Lamellipodia Formation, and Aggregate Stability Under Shear

(2013) Joseph E. Aslan et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Brutonˈs tyrosine kinase-an integral protein of B cell development that also has an essential role in the innate immune system

(2013) Gabriela López-Herrera et al.   JOURNAL OF LEUKOCYTE BIOLOGY

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

(2013) S Cheng et al.   LEUKEMIA

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies

(2013) Valkal Bhatt et al.   PHARMACOTHERAPY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct and overlapping functional roles of Src family kinases in mouse platelets

(2012) S. SÉVERIN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation

(2011) J. E. Aslan et al.   BLOOD

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

Signaling During Platelet Adhesion and Activation

(2010) Zhenyu Li et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The Src, Syk, and Tec family kinases: Distinct types of molecular switches

(2010) J. Michael Bradshaw   CELLULAR SIGNALLING